1 week Ago By ABMN Staff
Norges Bank bought a new position in ADMA Biologics, Inc. ( NASDAQ:ADMA – Free Report ) in the 4th quarter, Holdings Channel reports. The firm bought 119,344 shares of the biotechnology company’s stock, valued at approximately $2,047,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in ADMA. Lord Abbett & CO. LLC purchased a new stake in ADMA Biologics in the third quarter worth about $61,858,000.
Raymond James Financial Inc. purchased a new stake in shares of ADMA Biologics in the 4th quarter worth approximately $19,076,000. EWG Elevate Inc.
bought a new position in shares of ADMA Biologics during the fourth quarter valued at approximately $480,000. Allspring Global Investments Holdings LLC increased its holdings in ADMA Biologics by 1,144.4% during the fourth quarter.
Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock valued at $51,016,000 after buying an additional 2,613,482 shares during the period. Finally, Veracity Capital LLC raised its stake in ADMA Biologics by 117.0% in the fourth quarter.
Veracity Capital LLC now owns 46,415 shares of the biotechnology company’s stock worth $796,000 after buying an additional 25,030 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.
Analysts Set New Price Targets Separately, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th. ADMA Biologics Price Performance NASDAQ ADMA opened at $19.
40 on Friday. The firm’s fifty day simple moving average is $17.78 and its two-hundred day simple moving average is $18.
16. The firm has a market capitalization of $4.59 billion, a P/E ratio of 69.
29 and a beta of 0.53. The company has a current ratio of 7.
09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.
ADMA Biologics, Inc. has a 12-month low of $5.91 and a 12-month high of $23.
64. ADMA Biologics Company Profile ( Free Report ) ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Further Reading Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. ( NASDAQ:ADMA – Free Report ).
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter ..
